Respiratory syncytial virus human experimental infection model

Provenance, production, and sequence of low-Passaged memphis-37 challenge virus

Young In Kim Hoehamer, John Devincenzo, Bart G. Jones, Rajeev Rudraraju, Lisa Harrison, Rachel Meyers, Jeff Cehelsky, Rene Alvarez, Julia L. Hurwitz

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in children and is responsible for as many as 199,000 childhood deaths annually worldwide. To support the development of viral therapeutics and vaccines for RSV, a human adult experimental infection model has been established. In this report, we describe the provenance and sequence of RSV Memphis-37, the low-passage clinical isolate used for the model's reproducible, safe, experimental infections of healthy, adult volunteers. The predicted amino acid sequences for major proteins of Memphis-37 are compared to nine other RSV A and B amino acid sequences to examine sites of vaccine, therapeutic, and pathophysiologic interest. Human T- cell epitope sequences previously defined by in vitro studies were observed to be closely matched between Memphis-37 and the laboratory strain RSV A2. Memphis-37 sequences provide baseline data with which to assess: (i) virus heterogeneity that may be evident following virus infection/transmission, (ii) the efficacy of candidate RSV vaccines and therapeutics in the experimental infection model, and (iii) the potential emergence of escape mutants as a consequence of experimental drug treatments. Memphis-37 is a valuable tool for pre-clinical research, and to expedite the clinical development of vaccines, therapeutic immunomodulatory agents, and other antiviral drug strategies for the protection of vulnerable populations against RSV disease.

Original languageEnglish (US)
Article numbere113100
JournalPloS one
Volume9
Issue number11
DOIs
StatePublished - Nov 21 2014

Fingerprint

Human respiratory syncytial virus
Respiratory Syncytial Viruses
Viruses
provenance
Theoretical Models
viruses
Infection
infection
Respiratory Syncytial Virus Vaccines
Virus Diseases
Amino Acid Sequence
Vaccines
therapeutics
Viral Vaccines
Therapeutics
vaccines
Infectious Disease Transmission
T-Lymphocyte Epitopes
Vulnerable Populations
varespladib methyl

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Respiratory syncytial virus human experimental infection model : Provenance, production, and sequence of low-Passaged memphis-37 challenge virus. / Kim Hoehamer, Young In; Devincenzo, John; Jones, Bart G.; Rudraraju, Rajeev; Harrison, Lisa; Meyers, Rachel; Cehelsky, Jeff; Alvarez, Rene; Hurwitz, Julia L.

In: PloS one, Vol. 9, No. 11, e113100, 21.11.2014.

Research output: Contribution to journalArticle

Kim Hoehamer, YI, Devincenzo, J, Jones, BG, Rudraraju, R, Harrison, L, Meyers, R, Cehelsky, J, Alvarez, R & Hurwitz, JL 2014, 'Respiratory syncytial virus human experimental infection model: Provenance, production, and sequence of low-Passaged memphis-37 challenge virus', PloS one, vol. 9, no. 11, e113100. https://doi.org/10.1371/journal.pone.0113100
Kim Hoehamer, Young In ; Devincenzo, John ; Jones, Bart G. ; Rudraraju, Rajeev ; Harrison, Lisa ; Meyers, Rachel ; Cehelsky, Jeff ; Alvarez, Rene ; Hurwitz, Julia L. / Respiratory syncytial virus human experimental infection model : Provenance, production, and sequence of low-Passaged memphis-37 challenge virus. In: PloS one. 2014 ; Vol. 9, No. 11.
@article{2f04fd181ff643fba1d8e2711d503d9f,
title = "Respiratory syncytial virus human experimental infection model: Provenance, production, and sequence of low-Passaged memphis-37 challenge virus",
abstract = "Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in children and is responsible for as many as 199,000 childhood deaths annually worldwide. To support the development of viral therapeutics and vaccines for RSV, a human adult experimental infection model has been established. In this report, we describe the provenance and sequence of RSV Memphis-37, the low-passage clinical isolate used for the model's reproducible, safe, experimental infections of healthy, adult volunteers. The predicted amino acid sequences for major proteins of Memphis-37 are compared to nine other RSV A and B amino acid sequences to examine sites of vaccine, therapeutic, and pathophysiologic interest. Human T- cell epitope sequences previously defined by in vitro studies were observed to be closely matched between Memphis-37 and the laboratory strain RSV A2. Memphis-37 sequences provide baseline data with which to assess: (i) virus heterogeneity that may be evident following virus infection/transmission, (ii) the efficacy of candidate RSV vaccines and therapeutics in the experimental infection model, and (iii) the potential emergence of escape mutants as a consequence of experimental drug treatments. Memphis-37 is a valuable tool for pre-clinical research, and to expedite the clinical development of vaccines, therapeutic immunomodulatory agents, and other antiviral drug strategies for the protection of vulnerable populations against RSV disease.",
author = "{Kim Hoehamer}, {Young In} and John Devincenzo and Jones, {Bart G.} and Rajeev Rudraraju and Lisa Harrison and Rachel Meyers and Jeff Cehelsky and Rene Alvarez and Hurwitz, {Julia L.}",
year = "2014",
month = "11",
day = "21",
doi = "10.1371/journal.pone.0113100",
language = "English (US)",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

TY - JOUR

T1 - Respiratory syncytial virus human experimental infection model

T2 - Provenance, production, and sequence of low-Passaged memphis-37 challenge virus

AU - Kim Hoehamer, Young In

AU - Devincenzo, John

AU - Jones, Bart G.

AU - Rudraraju, Rajeev

AU - Harrison, Lisa

AU - Meyers, Rachel

AU - Cehelsky, Jeff

AU - Alvarez, Rene

AU - Hurwitz, Julia L.

PY - 2014/11/21

Y1 - 2014/11/21

N2 - Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in children and is responsible for as many as 199,000 childhood deaths annually worldwide. To support the development of viral therapeutics and vaccines for RSV, a human adult experimental infection model has been established. In this report, we describe the provenance and sequence of RSV Memphis-37, the low-passage clinical isolate used for the model's reproducible, safe, experimental infections of healthy, adult volunteers. The predicted amino acid sequences for major proteins of Memphis-37 are compared to nine other RSV A and B amino acid sequences to examine sites of vaccine, therapeutic, and pathophysiologic interest. Human T- cell epitope sequences previously defined by in vitro studies were observed to be closely matched between Memphis-37 and the laboratory strain RSV A2. Memphis-37 sequences provide baseline data with which to assess: (i) virus heterogeneity that may be evident following virus infection/transmission, (ii) the efficacy of candidate RSV vaccines and therapeutics in the experimental infection model, and (iii) the potential emergence of escape mutants as a consequence of experimental drug treatments. Memphis-37 is a valuable tool for pre-clinical research, and to expedite the clinical development of vaccines, therapeutic immunomodulatory agents, and other antiviral drug strategies for the protection of vulnerable populations against RSV disease.

AB - Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in children and is responsible for as many as 199,000 childhood deaths annually worldwide. To support the development of viral therapeutics and vaccines for RSV, a human adult experimental infection model has been established. In this report, we describe the provenance and sequence of RSV Memphis-37, the low-passage clinical isolate used for the model's reproducible, safe, experimental infections of healthy, adult volunteers. The predicted amino acid sequences for major proteins of Memphis-37 are compared to nine other RSV A and B amino acid sequences to examine sites of vaccine, therapeutic, and pathophysiologic interest. Human T- cell epitope sequences previously defined by in vitro studies were observed to be closely matched between Memphis-37 and the laboratory strain RSV A2. Memphis-37 sequences provide baseline data with which to assess: (i) virus heterogeneity that may be evident following virus infection/transmission, (ii) the efficacy of candidate RSV vaccines and therapeutics in the experimental infection model, and (iii) the potential emergence of escape mutants as a consequence of experimental drug treatments. Memphis-37 is a valuable tool for pre-clinical research, and to expedite the clinical development of vaccines, therapeutic immunomodulatory agents, and other antiviral drug strategies for the protection of vulnerable populations against RSV disease.

UR - http://www.scopus.com/inward/record.url?scp=84913590251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84913590251&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0113100

DO - 10.1371/journal.pone.0113100

M3 - Article

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e113100

ER -